Get The Spin Brief
CRISPRMRIimmunotherapyclinical trialorganoidsbiological age
Public companyCompany profile · informational

Moderna

Moderna develops mRNA medicines and markets vaccines against COVID-19 and RSV. With Merck, it is developing intismeran autogene, an individualized neoantigen mRNA cancer vaccine that has reported positive Phase 3 results in melanoma.

Verified highlights each with its source

  • mRESVIA (mRNA-1345) is FDA-approved to prevent RSV lower respiratory tract disease in adults 60 and older and at-risk adults 18–59.
    Source: fda.gov ↗
  • On Aug. 19, 2026, Merck and Moderna announced the Phase 3 INTerpath-001 trial (NCT05933577) of intismeran autogene plus Keytruda met its primary endpoint of recurrence-free survival in resected high-risk melanoma (company release).
    Source: merck.com ↗

Sources

  1. en.wikipedia.orgen.wikipedia.org
  2. fda.govfda.gov
  3. clinicaltrials.govclinicaltrials.gov

Science and stocks are different questions. This profile describes scientific and regulatory progress. It says nothing about whether the company’s shares will rise or fall, and it is not a recommendation to buy, sell or hold any security.

Disclosure. Spin Pharma has no financial relationship with this company and holds no position in it.

Related

Coverage mentioning this company